J 2021

Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide

KOSTAL, Milan, Jiri SCHWARZ, Petra OVESNÁ, Miroslav PENKA, Petr DULICEK et. al.

Basic information

Original name

Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide

Authors

KOSTAL, Milan (203 Czech Republic, guarantor), Jiri SCHWARZ (203 Czech Republic), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Miroslav PENKA (203 Czech Republic, belonging to the institution) and Petr DULICEK (203 Czech Republic)

Edition

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, DORDRECHT, SPRINGER, 2021, 0929-5305

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.221

RIV identification code

RIV/00216224:14110/21:00120658

Organization unit

Faculty of Medicine

DOI

UT WoS

000542529200001

Keywords in English

Stroke; TIA; Myeloproliferation; Thrombosis; Risk factor; JAK2

Tags

Tags

International impact, Reviewed
Změněno: 24/10/2022 08:53, Mgr. Tereza Miškechová

Abstract

V originále

Arterial thrombosis is a common complication in patients with Ph(-)myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34-76) and of 53 years of age (ranging from 26-74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458-3.043, p = 0.006), age (OR 1.017/year, 1.005-1,029, p = 0.006), male gender (OR 1.419, 1.057-1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446-0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473-0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162-2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017-3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph-MPN patients.